Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Adenoviral Vector Ad5-CEA Vaccine · ETBX-011

Vaccine (Adenoviral vector) · Immune activation, directed at carcinoembryonic antigen (CEA) (CEACAM5) · developed by ImmunityBio

Phase 1/2 Most advanced trial (none active)

IBRX Developer

1 Registered trials

What is Adenoviral Vector Ad5-CEA Vaccine?

ETBX-011 is a replication-defective adenoviral serotype 5 vaccine encoding a carcinoembryonic antigen (CEA) epitope. It induces humoral and cellular immune responses against CEA-expressing tumor cells. The vaccine is studied in head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ETBX-011
Drug type: Vaccine (Adenoviral vector)
Targets: carcinoembryonic antigen (CEA) (CEACAM5) (antigen)
Mechanism: Immune activation, directed at carcinoembryonic antigen (CEA) (CEACAM5)
Pathways: immune activation, cellular immunity, humoral immunity
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: RP9RQ0SOM8

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03169764	Phase 1/2	Head and Neck Squamous Cell Carcinoma	Withdrawn	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck Squamous Cell Carcinoma

Other drugs acting on CEACAM5

AN4035 Phase 1

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2 GI-4000 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind Adenoviral Vector Ad5-CEA Vaccine

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z